Study results from Drs. Kwasi Ofori and Kiran Turaga found #PeritonealMetastases often evade detection by ctDNA assays, despite occurring in up to 9.4% of patients with stage III #ColonCancer. medicine.yale.edu/cancer/publi... @annsurgoncology.bsky.social

A new study from @rongfan8.bsky.social and Dr. Sidi Chen shows how spatial CRISPR screening could advance #CancerResearch by revealing how genes and RNA interact within tumors, offering new insights into tumor growth, immune evasion, and RNA regulation. medicine.yale.edu/cancer/publi...

Scientists have identified proteins that could signal increased #lungcancer risk and a drug that could reduce the odds of a tumor developing. “This is the big ‘if,’” said Dr. Roy Herbst. "Will it be clinically significant?” nytimes.com/2026/06/04/w... @nytimes.com

Congratulations to Nikolai Podoltsev, MD, PhD, @yale-hematology.bsky.social who was presented with The Fred S. Kantor Teacher of the Year Award by the residents of the @yaleschoolofmed.bsky.social internal medicine traditional residency program!

Congratulations to @yaleschoolofmed.bsky.social student Aniketh Tadepalli of the #GoshuaLab, as he was selected as a recipient of an @ash.hematology.org HONORS (Hematology Opportunities for the Next Generation of Research Scientists) Award. @yale-hematology.bsky.social #ASHAwards #Fight4Hematology

Dr. Jensa Morris joined @thecurbsiders.bsky.social podcast for "Oncology for the Hospitalist" and discussed topics like symptom management, prognosis, and hospice care. thecurbsiders.com/curbsiders-p...

The new President of @ascocancer.bsky.social, Dr. Beth Mittendorf #ASCOPres, joins #YaleCancerAnswers tonight at 7:30pm to discuss exciting developments from the recent #ASCO26 Annual Meeting. 🎧 Listen live #WNPR 🔁 Download via #ApplePodcasts 💻 Listen later #YouTube @danafarber.bsky.social

A study from Drs. @mleapman.bsky.social + Xiaomei Ma @yalesph.bsky.social highlights how PSMA-PET imaging may shift #prostatecancer treatment patterns by detecting previously hidden metastases. medicine.yale.edu/cancer/publi... @carygross.bsky.social

Results from Dr. Amer Zeidan + colleagues in @nejm.org demonstrate an all-oral regimen of decitabine–cedazuridine plus venetoclax is a viable treatment option for pts with #AML. 47% of pts achieved CR, 63% had a complete or partial response. medicine.yale.edu/cancer/publi... @oncoalert.bsky.social

Findings from a study by Dr. Barbara Burtness highlight #amivantamab as a promising treatment option for patients with recurrent or metastatic #HNSCC who have exhausted standard therapies. medicine.yale.edu/cancer/publi... #ASCO26 #JCO

@adrianakahn.bsky.social shared data on a phase Ib trial #ASCO26: SIMONE (NCT06963905) tests whether adding #immunotherapy to sacituzumab govitecan (SG) can improve outcomes in metastatic triple negative breast cancer #TNBC. @ascocancer.bsky.social @oncoalert.bsky.social

Dr. Veda Giri will present 'Clinical Implications of Germline Variants in #ProstateCancer' and also serve as a panelist in an oral abstract session this morning at 11:21am CDT. meetings.asco.org/meetings/202... @ascocancer.bsky.social #ASCO26

Stem cell transplantation is the most cost-effective option for long-term care of #sicklecelldisease in adults compared to gene therapy and standard of care treatment, according to new research from Dr. George Goshua published in #BloodPortfolio. ➡️https://bit.ly/4dJ8sQn @yale-hematology.bsky.social

At 9:45am CDT #ASCO26, Dr. Amer Zeidan will co-chair and moderate the Q&A for an oral abstract session on #Leukemia, #MyelodysplasticSyndromes, and #Allotransplant. meetings.asco.org/meetings/202... @yale-hematology.bsky.social @ascocancer.bsky.social

Great talk by @sundarraghav.bsky.social at #ASCO26 on “Breaking the Immune Sanctuary: Targeting Metastatic Niches.” Metastasis may not be random—immune & cellular niches matter and can limit #immunotherapy responses, underscoring the need for better treatment strategies. @oncoalert.bsky.social

@adrianakahn.bsky.social reported primary #breastcancer tumors + skin mets share many of the same DNA changes, though skin mets more often had alterations linked to estrogen signaling and tumor spread. #ASCO26 @ascocancer.bsky.social @oncoalert.bsky.social

Dr. Tamar Kaminski shared that ~1 in 10 women ≥65 with advanced #breastcancer had an HRD genomic signature, potentially identifying patients for PARP inhibitor therapy. HRD+ tumors were enriched for BRCA1/2 and other DNA-repair alterations. #ASCO26 @ascocancer.bsky.social @oncoalert.bsky.social

Dr. Maryam Mooghali shares how commercial pricing for biomarker tests varies substantially across US hospitals, insurers. Variation is greater between hospitals than within for the same test—with implications for patient costs, equitable access to #cancer care. #ASCO26 @oncoalert.bsky.social

Dr. David Rimm @yalepathology.bsky.social #ASCO26 discussed new data on #AI “reading” standard #pathology slides to infer molecular signals requiring extra lab tests, a potentially faster method-though not yet a replacement for today’s validated diagnostics. @oncoalert.bsky.social

Drs. Alessandro Santin and Stefania Bellone share promising data on a phase 2 study (NCT06028932) of sacituzumab govitecan for #ovariancancer: 35% had tumor shrinkage and 40% had stable disease in 20 heavily pretreated patients. #ASCO26 @ascocancer.bsky.social @oncoalert.bsky.social

Stop by Hall A this afternoon at 1:30pm CDT as we have 4 presenters sharing research updates and study results: Drs. @nicholasblondin.bsky.social; Sylvia Kurz; Tamar Kaminski; and @adrianakahn.bsky.social @ascocancer.bsky.social

Dr. Durga Sritharan shows how using #AI on #ovariancancer pathology slides flags tumors likely to resist platinum chemo (about 1/5 pts). 79% “Predicted sensitive” slides were correct, supporting low-cost tool to personalize treatment earlier.#ASCO26 @yalepathology.bsky.social @oncoalert.bsky.social

@sundarraghav.bsky.social chaired an education session on Targeting Metastatic Niches and also will present 'Foundations of Premetastatic Niche Formation' today at 1:15pm CDT #ASCO26. meetings.asco.org/meetings/202... @ascocancer.bsky.social

Dr. Gabriela Esnaola shares a study of metastatic #NSCLC showing patterns where cancer spreads predict survival & treatment response better than looking at single organs. This “metastasis profile” approach could improve therapy decisions. #ASCO26 @ascocancer.bsky.social @oncoalert.bsky.social

“ #ctDNA is a really promising tool for the future, but it’s really hard to know how to use it in #breastcancer care right now. It will change our entire approach. We just need more time to evaluate it,” -Dr. Eric Winer. #ASCO26 @ascocancer.bsky.social @oncoalert.bsky.social

Dr. Eric Winer moderates a case-based panel at #ASCO26 exploring mgmt of advanced/metastatic HER2+ #breastcancer, highlighting how cancer progression, treatment response, therapy options, + patient preferences & decisions, shape treatment goals. @ascocancer.bsky.social @oncoalert.bsky.social

Dr. David Rimm presents an oral abstract this morning at 9:36am CDT #ASCO26: 'Artificial Intelligence and Spacial Profiling: Redefining Predictive Biomarkers.' meetings.asco.org/meetings/202... @yalepathology.bsky.social @ascocancer.bsky.social

We have 5 poster presentations scheduled for this morning's #ASCO26 9am CDT poster session in Hall A, featuring Drs. Maryam Mooghali; Gabriela Esnaola; Kwame Adjei-Sefah; Alessandro Santin; and Durga Sritharan. @ascocancer.bsky.social

Dr. Eric Winer chairs and moderates a Case-Based Panel this morning at 8am CDT #ASCO26 on 'De Novo HER2 Metastatic #BreastCancer: Cure or Control.' meetings.asco.org/meetings/202... @ascocancer.bsky.social

Wonderful evening at #ASCO26 connecting with colleagues and catching up with friends at our annual reception. More photos to come! @ascocancer.bsky.social

Dr. Harriet Kluger discussed the immense promise of cellular therapies, BiTEs, and therapies targeting cell surface proteins #ASCO26, pushing for durable, long term responses, additional targets, and more applications. @ascocancer.bsky.social @oncoalert.bsky.social

Dr. Sarah Goldberg presents early COPERNICUS safety results suggesting subcutaneous amivantamab every 4 weeks + daily lazertinib for newly diagnosed EGFR-mutant advanced #lungcancer may be easier to tolerate with proactive supportive care. #ASCO26 @ascocancer.bsky.social @oncoalert.bsky.social

Promising news announced #ASCO26 for patients with #lungcancer. Dr. Roy Herbst comments on ivonescimab, noting the initial study results from China are clinically meaningful. via @bloomberg.com @robertlangreth.bsky.social @ascocancer.bsky.social www.bloomberg.com/news/article...

At #ASCO26, Drs. Soki Kashima and David Braun share why some #kidneycancer tumors don’t respond to immunotherapy despite having plenty of T cells: many T cells are “exhausted” and unable to fight cancer effectively, likely due to TGF-β signaling. @ascocancer.bsky.social @oncoalert.bsky.social

Dr. Mehra Golshan joins #YaleCancerAnswers tonight at 7:30pm to talk about the advancements in #breastcancer surgery, lumpectomy, plus reconstruction. 🎧Listen live #WNPR 🔁Download via #ApplePodcasts 💻Listen later #YouTube

Dr. Barbara Burtness presented impressive results from OrigAMI-4 (ph 1b/2) in HPV-unrelated recurrent/met head & neck cancer #ASCO26: #amivantamab had an ORR of 42%, 15% complete response, & 79% had some tumor shrinkage. Responses were fast & durable. @ascocancer.bsky.social @oncoalert.bsky.social

Dr. Daniel Petrylak shared Duravelo-2 interim results at #ASCO26: BT8009, a targeted therapy for advanced bladder cancer, helped shrink tumors in about 3 in 10 pts whose cancer had already been treated. @ascocancer.bsky.social @oncoalert.bsky.social

Drs. David Braun & Zachary Yochum at #ASCO26: Spatial multi-omics mapping of #kidney tumors showed aggressive rhabdoid/sarcomatoid regions are rich in immune cells, with T cells that appear both activated and exhausted. @ascocancer.bsky.social @oncoalert.bsky.social

Dr. Roy Herbst highlights MarsLight-11 #ASCO26, a ph 3 trial in #NSCLC that has progressed after both chemo & immuno. It compares docetaxel vs IBI363, a new immune drug designed to block PD‑1 while also giving a targeted IL‑2 ‘boost.’ @ascocancer.bsky.social @oncoalert.bsky.social #lcsm

Dr. Aarti Bhatia discusses the impact of neoadjuvant and adjuvant therapy for head and neck cancer through a comprehensive review of data presented from the AREST, NIVOPOSTOP & MACE-POSTOP trials. #ASCO26 @ascocancer.bsky.social @oncoalert.bsky.social

This morning at 10:36am CDT #ASCO26, Dr. Harriet Kluger presents an oral abstract, 'Finding the Right Cellular #Immunotherapy.' meetings.asco.org/meetings/2026-… @ascocancer.bsky.social

Dr. Barbara Burtness will be presenting results from the phase 1b/2 OrigAMI-4 study on #Amivantamab this morning at 10:24am CDT #ASCO26. meetings.asco.org/meetings/2026-… @ascocancer.bsky.social

Stop into Hall A at #ASCO26 this morning at 9am CDT to support our poster presenters and their research: Drs. Daniel Petrylak; Sarah Goldberg; Giorgio Caturgli; Zachary Yochum; Soki Kashima; and Dr. Roy Herbst. @ascocancer.bsky.social

Dr. Aarti Bhatia presents 'Optimizing Adjuvant Therapy in Head and Neck Cancer' this morning at 8:36am CDT #ASCO26. meetings.asco.org/meetings/2026-… @ascocancer.bsky.socia#ASCO2626

Dr. Barbara Burtness presented #ASCO26 abstract #6008 on subcutaneous amivantamab for HPV-unrelated recurrent/metastatic head & neck squamous cell cancer after immunotherapy + platinum chemo. @ascbiology.bsky.social meetings.asco.org/meetings/2026-…

Yale research led by Drs. Shira Gabizon Peretz and Harriet Kluger found an inherited NLRC5 variant (Pro191Leu) was more common in pts who developed ICI–induced hepatitis (30% vs 12.8% in the general pop). #ASCO26 @ascocancer.bsky.social @oncoalert.bsky.social

Presented by Drs. Curtis Pickering and Paris Abedi, specific tumor DNA changes may help predict outcomes for people with oral cavity cancer. TP53 and TERT mutations were linked to worse survival, while PIK3CA was linked to better outcomes. #ASCO26 @ascocancer.bsky.social @oncoalert.bsky.social

Dr. Harriet Kluger presents the phase 1 trial (NCT07027488) of AB821 at #ASCO26 for patients with advanced melanoma and other immune-responsive solid tumors. Accrual is ongoing. @ascocancer.bsky.social @oncoalert.bsky.social medicine.yale.edu/cancer/trial/a…

Dr. Barbara Burtness shared updated results from KEYNOTE‑412 in unresected locally advanced #HNSCC. In pts with high PD‑L1 expression, adding pembro to CRT improved outcomes vs CRT alone. #ASCO26 @ascocancer.bsky.social @oncoalert.bsky.social

Dr. David Braun + colleagues tested a “live tumor fragment” lab assay/elive platform using biopsies to predict response to ICI. #ASCO26 @ascocancer.bsky.social @oncoalert.bsky.social